An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan(University of North Carolina at Chapel Hill), Ralph S. Baric(University of North Carolina at Chapel Hill), Ronald Swanstrom(University of North Carolina at Chapel Hill), Natalie J. Thornburg(Oak Ridge Associated Universities), Rachel L. Graham(University of North Carolina at Chapel Hill), George R. Painter(Emory University), Collin S Hill(University of North Carolina at Chapel Hill), Jennifer L. Harcourt(Centers for Disease Control and Prevention), Tia M. Hughes(Vanderbilt University Medical Center), Azaibi Tamin(Centers for Disease Control and Prevention), Sarah R. Leist(University of North Carolina at Chapel Hill), Laura J. Stevens(Vanderbilt University Medical Center), Xiaotao Lu(Vanderbilt University Medical Center), Stephanie A. Montgomery(University of North Carolina at Chapel Hill), Amy Sims(Georgia State University), Kenneth H. Dinnon(University of North Carolina at Chapel Hill), Gregory R. Bluemling(Emory University), Alexander A. Kolykhalov(Emory University), Manohar Saindane(Emory University), Shuntai Zhou(University of North Carolina at Chapel Hill), Mark R. Denison(Bipar), Michael G. Natchus(Emory University), Amelia S. George(Vanderbilt University Medical Center), James D. Chappell(King Saud bin Abdulaziz University for Health Sciences), Maria L. Agostini(VIR Biotechnology (United States)), Ariane J. Brown(University of North Carolina at Chapel Hill), Alexandra Schäfer(University of North Carolina at Chapel Hill), Andrea J. Pruijssers(Vanderbilt Health)
Science Translational Medicine
April 6, 2020
Cited by 1,168


Related Papers